Our first-in-class biocompatible cryopreservation medium has been modified to enhance the cryopreservation
efficiency of red blood cells, eliminating the need for toxic cell-permeating cryoprotectants and the complicated
operations required by traditional blood banking methods. This novel technology will offer cost-saving and
efficient options for improved supply chain management in the biobanking of red blood cell units. In this project,
we aim to obtain qualifications related to Good Manufacturing Practice (GMP) production, biocompatibility, safety,
and efficacy testing, and secure 510(k) clearance to pave the path to commercialization.